Trials / Terminated
TerminatedNCT01937130
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Conatus Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of IDN-6556 in subjects with cirrhosis of the liver who are hospitalized for more than 24 hours due to acute deterioration of liver function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDN-6556 | |
| OTHER | Placebo |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2015-01-01
- Completion
- 2015-02-01
- First posted
- 2013-09-09
- Last updated
- 2016-04-11
- Results posted
- 2016-04-11
Locations
26 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT01937130. Inclusion in this directory is not an endorsement.